Results 51 to 60 of about 17,320 (202)

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Menstrual Wellbeing of Professional Workers: A Work Demands‐Resources Perspective

Human Resource Management Journal, EarlyView.
ABSTRACT Menstrual symptoms compromise the menstrual wellbeing of more than a quarter of the global workforce. However, to the best of our knowledge, the human resource management (HRM) literature, as well as the HR policy and practice, is almost silent on employee menstrual wellbeing.
Muhammad Shujahat, Rashedur Chowdury, Muhammad Saleem Ullah Khan Sumbal   +2 more
wiley   +1 more source

Diagnostic Strategies for Postmenopausal Bleeding

Obstetrics and Gynecology International, 2010
Postmenopausal bleeding (PMB) is a common clinical problem. Patients with PMB have 10%–15% chance of having endometrial carcinoma and therefore the diagnostic workup is aimed at excluding malignancy.
M. C. Breijer, A. Timmermans, H. C. van Doorn, B. W. J. Mol, B. C. Opmeer   +4 more
doaj   +1 more source

Is it safe to preserve uterus after live birth following progestin‐based fertility‐sparing treatment for endometrial cancer or atypical hyperplasia: A long‐term retrospective cohort study

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Achieving live birth following fertility‐sparing treatment is associated with improved recurrence‐free survival among patients with endometrial cancer/atypical endometrial hyperplasia. Abstract Introduction We aimed to assess the safety of continuous uterus‐preserving treatment among patients with endometrial cancer (EC) and atypical endometrial ...
Yiqin Wang, Yuanyuan Liu, Yifan Feng, Linlin Bo, Zerui Xiao, Haibo Wang, Li Tian, Qun Lu, Rong Zhou, Jianliu Wang   +9 more
wiley   +1 more source

A concept for a new approach to combined oral contraception from adolescence to perimenopause: Continuous use of the oral GnRH antagonist Relugolix and the fetal estrogen Estetrol

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
It is expected that the relugolix estetrol combination RE4W will enable women to control their fertility and prevent menstrual cycle related problems, while offering a smooth transition through perimenopause into the postmenopause and decrease the risk of breast cancer.
Herjan J. T. Coelingh Bennink, Karolina Afors, Luis Bahamondes, Alessandra Graziottin, Deborah Bateson, Teresa Bombas, Yutaki Osuga, Santiago Palacios, Carolyn L. Westhoff, Kristina Gemzell‐Danielsson   +9 more
wiley   +1 more source

Predictive Value of Endometrial Thickness in Detecting Endometrial Malignancy in Patients with Postmenopausal Bleeding

Haseki Tıp Bülteni, 2014
Aim: The aim of this study was to investigate the place of endometrial thickness in detecting endometrial malignancy in patients with postmenopausal vaginal bleeding.
Onur Kaya, Cem Dane, Ecem Kaya, Mehmet Murat Semiz, Ahmet Çetin, Gamze Saygı   +5 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer

Cancer Science, EarlyView.
We identified key endometrial cancer DNA methylation biomarkers (ZNF626, GRIA4, SPDYA) from cervical cells. The model achieved high endometrial cancer sensitivity and detected 92.86% of Stage I endometrial cancers using TCT samples. ABSTRACT Endometrial cancer, the most common gynecological malignancy with an annual increase of 1%–3%, lacks suitable ...
Yan Cai, Shuchao Chen, Zhen Wu, Jinxia Guan, Jie Zhao, Jianwei Ye, Baochen Du, Xiaoliang Han, Tong Shu, Guangpeng Zhou, Hong Zheng   +10 more
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Cardiovascular Health in Women—Across the Lifespan

Clinical Endocrinology, EarlyView.
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar, Jessica Yao, Simone Gong, Madhuka Wijayarathne, Monique Watts, Swati Mukherjee   +5 more
wiley   +1 more source